Weekly Issue — 2025-09-14

Here's the shift worth tracking. GLP-1 receptor agonists (GLP-1 RAs) were approved to lower blood sugar in type 2 diabetes (T2D), then became famous for weight loss. Now they're being positioned as cardiorenal drugs — medications that may slow the progression of chronic kidney disease (CKD) in people with diabetes. That repositioning is what the FOUNTAIN multinational cohort study set out to document: not whether GLP-1s work for kidney protection, but who is actually starting them, and where.

The answer, across five large data sources in Denmark, the Netherlands, Spain, Japan and the United States, is: a lot of people, and increasingly so. Between 2012 and 2021, researchers identified GLP-1 RA initiators with both T2D and CKD in numbers that climbed steadily over the decade — from a few hundred patients in the Japanese database up to roughly 70,158 initiators in the U.S. Clinformatics dataset. The mean age clustered in the mid-to-late sixties across every country. This is not, in other words, the TikTok demographic.

Chronic kidney disease is one of the most common — and most under-discussed — complications of type 2 diabetes. For decades, the kidney-protective toolkit was thin: blood pressure control, blood sugar control, and a class of blood-pressure drugs called ACE inhibitors or ARBs. The arrival of SGLT2 inhibitors changed that. GLP-1 RAs are now being studied as a second pillar, and the FOUNTAIN platform exists to map what that looks like outside a clinical trial — in actual clinics, with actual patients, on actual insurance.

A few things stand out. Uptake rose year over year across every region studied. The patient populations were broadly similar in age but differed in sex balance — from 46.6% men in the Dutch PHARMO cohort to 59.6% in the Japanese database — and in baseline characteristics that reflect each country's prescribing culture. That variation matters. Real-world cohorts aren't randomized trials; they describe the people doctors are choosing to treat, which is its own kind of data.

What the study does not do is prove that GLP-1s protect kidneys. It's a descriptive cohort, not an outcomes trial. The kidney-protection case rests on other evidence, and the language here should match: promising, increasingly used, not yet a slam dunk.

Anyone who has spent five minutes on GLP-1 forums has read some version of the same anecdote: food just doesn't sound as good. Wine tastes flat. The pull of a salty snack at 4 p.m. quietly evaporates. Researchers have largely chalked this up to delayed gastric emptying and central appetite signaling. A new study in Neuropharmacology raises another possibility: the taste system itself.

In wild-type mice, researchers used a viral vector to express GLP-1 receptor agonist exendin-4 and the gut peptide PYY directly in the salivary glands — essentially flooding the mouth with the satiety peptides that GLP-1 drugs mimic systemically. They then measured taste-related behavior. The result: significant changes in responsiveness across multiple taste qualities. In a separate in vitro arm, isolated taste bud cells appeared to respond to the peptides directly, suggesting the gustatory cells themselves carry the receptors.

It's a tidy mechanistic clue. If GLP-1-related peptides can change how a taste bud reports back to the brain, then part of the appetite shift people describe may originate not in the gut or the hypothalamus, but in the mouth.

Put the two studies together and a more layered version of the GLP-1 narrative emerges. The FOUNTAIN cohort tells us these drugs are being deployed in older adults with diabetes and kidney disease, in rising numbers, across very different health systems. The taste study reminds us that we still don't fully understand how they do what they do — and that the answer probably isn't one mechanism but several, layered on top of each other.

For readers, the honest takeaway is this: GLP-1s are looking less like a weight-loss product and more like a metabolic-disease platform. The evidence for kidney protection is moderate and growing. The evidence on taste rewiring is early, animal-only, and intriguing rather than established. And the question of whether any of this applies to a healthy 32-year-old curious about microdosing for vibes is — still, firmly — unanswered.

None of this is a prescription. If you have type 2 diabetes, kidney disease, or are weighing a GLP-1 for any reason, the conversation belongs in a clinic, not a comment section.

The reframing is striking. A 2025 review in Cancers describes metformin as undergoing a renaissance — no longer just a glucose-lowering drug, but a prototype gerotherapeutic and immunometabolic adjuvant: a molecule that appears to nudge the same biological levers implicated in aging and cancer. The authors synthesize decades of mechanistic work alongside data from landmark trials, and the picture that emerges is genuinely interesting. It is also, importantly, incomplete.

That distinction matters. Headlines have a habit of compressing "promising" into "proven," and metformin has been on the receiving end of more than its share of overreach. So let's walk through what the evidence actually says — and what it doesn't — for women thinking carefully about the back half of life.

Aging, in the modern biological view, is not a single process but a network of intertwined ones: chronic low-grade inflammation, mitochondrial drift, accumulating senescent cells, epigenetic noise, an immune system that grows both irritable and inattentive. Drugs that meaningfully touch several of these levers at once are rare. Metformin, somewhat improbably, appears to be one of them.

According to the Cancers review, metformin modulates an integrated network of metabolic, immunological, microbiome-mediated, and epigenetic pathways that overlap with the recognized hallmarks of aging and cancer biology. In plain language: it doesn't just lower blood sugar. It seems to quiet some of the background hum that drives age-related disease.

That mechanistic breadth is the reason serious researchers — not wellness influencers — have spent years trying to design a trial big enough to test whether metformin can actually extend the years a person spends in good health.

Three trials anchor the clinical case. The first is UKPDS, the long-running U.K. diabetes study that first signaled metformin could reduce cardiovascular events in people with type 2 diabetes — a finding that has shaped prescribing for a generation. The second, CAMERA, looked at cardiometabolic markers in non-diabetic patients and helped fuel interest in metformin's effects beyond glucose control.

The third — and the one the longevity field is genuinely waiting on — is TAME (Targeting Aging with Metformin). TAME is designed to test whether metformin can delay the onset of multiple age-related diseases at once, rather than treating each in isolation. If it succeeds, it won't just be a result about a drug. It will be the first regulatory-grade evidence that aging itself can be slowed by a pharmaceutical. That is a very big if, and the trial is ongoing.

In oncology, separate trials including MA.32 and METTEN are evaluating metformin's influence on progression-free survival and tumor response, particularly as an adjuvant alongside standard cancer therapy. The Cancers review also notes clinical data suggesting metformin can reduce cancer incidence, enhance immunotherapy outcomes, delay multimorbidity, and reverse biological age markers — a remarkable list, and one that should be read in the spirit it was written: as a synthesis of accumulating signals, not a finished verdict.

One of the more provocative claims in the 2025 review is that metformin appears to reverse certain biological age markers — the epigenetic and metabolic readouts researchers use as proxies for how old your cells "act," as opposed to how old your driver's license says you are. This is the kind of finding that lights up longevity Twitter. It deserves a calmer reading.

Biological-age clocks are still maturing as a science. Different clocks disagree with one another. A drug that moves a clock is not the same as a drug that adds healthy years, and the field has not yet shown that nudging these markers reliably translates into longer healthspan in people who weren't sick to begin with. The signal is real and worth pursuing. It is not yet a recommendation.

For women navigating midlife and beyond, the honest position is this: metformin is one of the most studied, lowest-cost, longest-tolerated drugs in modern medicine, and it is being investigated with unusual seriousness as a possible tool for healthy aging. It is also a prescription drug with real side effects, real contraindications, and — for healthy adults without diabetes — no current regulatory indication for longevity.

If you live with type 2 diabetes, prediabetes, PCOS, or another condition for which metformin is already indicated, the conversation with your clinician is straightforward and well-trodden. If you are healthy and curious about metformin as a longevity tool, the conversation is different, more speculative, and one only your own physician can have with you — ideally with the TAME trial and its eventual readout in mind.

Metformin's second act is being written in real time. The most useful thing a reader can do right now is neither dismiss it nor rush it. Watch the trials. Ask good questions. And remember that the most powerful longevity interventions we have today — strength, sleep, protein, social connection, hormone-informed care — are still the ones with the deepest evidence behind them.

Here is the honest read: nothing in the 2025 literature should send you flushing your pen down the toilet. But three independent reports published this year point at the same uncomfortable truth — these drugs do things to the body that matter when the body is also being cut open, scoped, or scanned. The signals are small, the evidence is moderate, and the headlines are getting ahead of the data. That is exactly why it is worth slowing down and reading what is actually on the page.

The most provocative of the three reports comes out of the PearlDiver Mariner database. Researchers pulled 340 semaglutide users undergoing posterior cervical fusion and propensity-matched them 1:5 against 1,540 controls. After Bonferroni correction — a statistical haircut designed to keep researchers honest — semaglutide users had significantly higher odds of pseudarthrosis at two years (OR 4.79, 95% CI 3.11–7.37) and dysphagia (OR 2.12, 95% CI 1.46–3.03).

Pseudarthrosis is the surgeon's word for a fusion that never finishes fusing — two vertebrae that should have grown into one stubbornly refusing to merge. A nearly five-fold odds ratio is not a rounding error. It is the kind of number that, if it holds up in prospective work, changes pre-operative checklists.

Mechanistically, the why is still open. GLP-1 agonists alter nutrient signaling, suppress appetite hard enough to drive sarcopenic-style weight loss in some users, and may modulate bone turnover through pathways researchers are still untangling. For a lifter, the takeaway is narrower than the headline: if you are on semaglutide and a fusion is on your calendar, that is a conversation with your surgeon, not a Reddit thread.

The second signal is a single case, and case reports are the lowest tier of clinical evidence — they generate hypotheses, they do not confirm them. But this one is worth reading. A 66-year-old woman on semaglutide for obesity developed acute cholecystitis within 72 hours of a routine colonoscopy. The authors hang their hypothesis on a known piece of GLP-1 pharmacology: these drugs slow gallbladder motility. A sluggish gallbladder plus the mechanical and inflammatory stress of bowel prep and insufflation is a plausible setup for an acute attack.

What the authors call for — and what the field does not yet have — is data on whether a pre-procedure washout period would lower the risk. Right now, that question is unanswered. The case is one data point, not a protocol.

The third report is, in some ways, the most unsettling because the patient felt fine. An 83-year-old man on tirzepatide was sent for an 18F-FDG PET/CT to stage a basal cell carcinoma. The scan showed diffuse radiotracer uptake throughout the pancreas with no CT abnormality. A follow-up lipase came back elevated. Diagnosis: subclinical pancreatitis, no other cause identified, attributed to the GLP-1.

Pancreatitis risk has shadowed this drug class since the early exenatide days. Most large analyses have not found a slam-dunk association. But a case like this one — caught incidentally, biochemically real, completely asymptomatic — hints that we may be undercounting the milder end of the spectrum simply because nobody scans an asymptomatic patient on purpose.

Lifters tend to be high-information patients. You already weigh your chicken and track your creatine phosphate. Apply the same discipline here. None of these three reports is sufficient on its own to flip the risk-benefit calculus of GLP-1 use. Cardiovascular and metabolic upside in the right patient is real and well-documented elsewhere. But the moderate-strength pattern emerging from 2025 is that these drugs interact with procedures — surgical, endoscopic, even imaging — in ways the original trials did not have power to detect.

The practical move is procedural, not pharmacological. Tell every clinician you see that you are on it. Bring it up before colonoscopy. Bring it up before any orthopedic or spinal surgery. Bring it up before any imaging that might pick up an incidental finding you would otherwise miss. The drugs are not the enemy. Information asymmetry is.

The peptide era is not slowing down. If anything, the next 18 months will bring oral formulations, dual and triple agonists, and use cases that stretch well beyond diabetes and obesity. The smart play for anyone using these compounds — for cuts, for metabolic health, for longevity bets — is to treat the safety literature the same way you treat training data. Read it as it comes out. Update the model. Do not over-fit on a single case report, and do not ignore a signal because it is inconvenient.

The drugs work. The complication file is still being written. Both things are true.